Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Influenza worsens AMI outcomes

13 Nov 2019

Patients with acute myocardial infarction (AMI) are likely to suffer from worse clinical outcomes in the presence of influenza and other viral infections, a recent study has shown.

Drawing from the National Inpatient Sample, researchers identified 1,884,985 AMI admission, 1.1 percent of whom were positive for infections. There were 9,885 AMI patients with influenza (mean age, 72.3±14.0 years; 47.8 percent female) and 11,485 with other viral respiratory infections (mean age, 71.9±14.2 years; 48.4 percent female).

Clinical outcomes were worst in patients who had concomitant influenza. In-hospital case fatality rate, for example, was highest in these patients as opposed to those with other viral respiratory infections and without any viral infections (13.5 percent vs 7.5 percent and 8.6 percent; p<0.001).

The same was true for acute respiratory failure (19.2 percent vs 10.1 percent and 10.2 percent; p<0.001), acute kidney injury (40.3 percent vs 31.0 percent and 24.2 percent; p<0.001) and length of stay (9.3±10.3 vs 7.5±8.6 and 5.8±7.3 days; p<0.001), among other important outcome measures.

These differences remained significant even after propensity-score adjustment.

Relative to those without concomitant influenza, AMI patients with the infection were more likely to die while admitted (13.2 percent vs 9.6 percent; p<0.001) and to develop acute respiratory failure (53.0 percent vs 28.8 percent; p<0.001) and acute kidney injury (40.2 percent vs 28.6 percent; p<0.001).

These findings were generally untrue in AMI patients who had other viral respiratory infections, except for acute respiratory failure, which occurred at a much higher frequency than in the no-infection comparators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 4 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.